1. Home
  2. TENX vs BARK Comparison

TENX vs BARK Comparison

Compare TENX & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$1.48

Market Cap

73.8M

Sector

Health Care

ML Signal

N/A

Logo BARK Inc.

BARK

BARK Inc.

SELL

Current Price

$9.47

Market Cap

73.7M

ML Signal

SELL

Company Overview

Basic Information
Metric
TENX
BARK
Founded
1967
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Department/Specialty Retail Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
73.8M
73.7M
IPO Year
2001
2020

Fundamental Metrics

Financial Performance
Metric
TENX
BARK
Price
$1.48
$9.47
Analyst Decision
Buy
Strong Buy
Analyst Count
10
2
Target Price
$10.29
★ $17.00
AVG Volume (30 Days)
★ 1.4M
29.9K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $394,843,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$4.03
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.31
$0.50
52 Week High
$19.40
$11.32

Technical Indicators

Market Signals
Indicator
TENX
BARK
Relative Strength Index (RSI) 35.62 64.62
Support Level $1.34 $8.14
Resistance Level $2.01 $9.98
Average True Range (ATR) 0.12 0.56
MACD 0.00 0.14
Stochastic Oscillator 6.25 74.31

Price Performance

Historical Comparison
TENX
BARK

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About BARK BARK Inc.

BARK Inc believe that dogs and humans are good together and it aspire to be the world's favorite dog brand. It is a team of dog-obsessed people committed to delivering personalization at scale by satisfying each dog's distinct personality, preferences, and needs with the products and services. It is an omnichannel brand that designs and develops proprietary products for dogs across two key brands: BarkBox and Super Chewer. All of its products are designed and developed in-house, and are BARK branded. Its segments are DTC, and Commerce. It generates majority of revenue from DTC. Direct to Consumer generates revenue from subscription products that feature monthly themes of premium quality BarkBox and Super Chewer toys and BARK-branded treats and chews.

Share on Social Networks: